


ACIP COVID-19 Vaccines Work Group

COVID-19 vaccine implementation


Nancy Messonnier, MD July 29, 2020





Rising to the challenge to achieve high coverage with COVID-19 vaccines

Influenza Vaccination Coverage, ≥18 years, by Race/Ethnicity: 2008-09 – 2017-18



- Vaccination coverage of racial and ethnic minorities is consistently lower than that of white populations
- We need novel and more robust strategies to increase uptake of COVID-19 vaccine, once one becomes available

*Other includes Asian, American Indian/Alaska Native, and multiple race.




Source: Vaccination Coverage among Adults in the United States, National Health Interview Survey, CDC, 2017. NH = Non-Hispanic. Vaccinations included in this assessment include influenza, pneumococcal, Td, Tdap, Zoster, HepA, HepB, and HPV.

Complex and evolving landscape for COVID-19 vaccine


- One vs. two dose series, products not interchangeable
- Varying presentations
- Vaccine efficacy and adverse event profile in different populations
- Varying cold-chain requirements
- Use in children and pregnant women
- Need for socially distanced vaccination practices
- Communication and education
- High-risk groups for COVID-19 may distrust public health




Multiple Critical Components to Vaccine Implementation



As volume of doses available increases, we will be able to vaccinate broader populations



Approach to COVID-19 vaccination





To distribute and administer a COVID-19 vaccine, we will leverage many opportunities to ensure success

Partnerships with distributor(s)
will ensure the vaccine is
readily and efficiently
distributed across the country

Distributor(s) Partners Sites

State, local, and community partners will be instrumental in planning for widespread vaccination

Diverse administration sites (pharmacies, doctor's offices, mobile clinics, etc.) will ensure all individuals have physical access to the vaccine

IT infrastructure will support the entire vaccine ordering, distribution, and tracking process from end-to-end



The Vaccine Life Cycle safety at every phase GUIDE

PRACTICES BLA

ACIP ADVISORY COMMITTEE ON IMMUNIZATION

BIOLOGICS LICENSE APPLICATION

CDC

CENTERS FOR DISEASE CONTROL AND PREVENTION

FDA

FOOD AND DRUG ADMINISTRATION

IND

INVESTIGATIONAL NEW DRUG APPLICATION

BASIC

VACCINE

safety continues with CDC + FDA safety monitoring

safety is a priority during vaccine development + approval

DISCOVERY PRE-CLINICAL RESEARCH STUDIES

PHASE 1 PHASE 2 safety

effectiveness safety + effectivéness

PHASE 3

CLINICAL STUDIES / TRIALS

FDA APPROVAL OF INEW VACCINE ACID RECOMMENDATION ACIP REVIEW

safety monitoring for serious, unexpected adverse events

PHASE 4

POST-APPROVAL MONITORING + RESEARCH






LEARN MORE

FDA VACCINE DEVELOPMENT + APPROVAL PROCESS http://go.usa.gov/xvvNd CDC VACCINE SAFETY MONITORING + RESEARCH http://go.usa.gov/xvvNe

FDA REVIEW



CDC's strategic framework for strengthening vaccine confidence and preventing outbreaks of vaccine preventable diseases.

Protect communities

Strategy: Protect communities at risk from under-vaccination

- ✓ Leverage immunization data to find and respond to communities at risk
- ✓ Work with trusted local partners to reach at-risk communities before outbreaks
- ✓ Ensure vaccines are available, affordable, and easy-to-get in every community

Empower families


Strategy: Get providers and parents effective information resources

- Expand resources for health care professionals to help them have effective vaccine conversations with parents
- ✓ Work with partners to start conversations before the first vaccine appointment
- ✓ Help providers foster a culture of immunization in their practices

Stop myths

Strategy: Stop misinformation from eroding public trust in vaccines

- ✓ Work with local partners and trusted messengers to improve confidence in vaccines among key, at-risk groups
- ✓ Establish partnerships to contain the spread of misinformation
- ✓ Educate key new stakeholders (e.g., state policy makers) about vaccines



For more information, contact CDC 1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

Thank you

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

